Beijing Hotgen Biotech Co Ltd (688068) — Capital Reinvestment Ratio
Beijing Hotgen Biotech Co Ltd (688068) has a Capital Reinvestment Ratio of 4.82x as of September 2025, meaning it reinvests 5% of its operating cash flow (CN¥3.05 Million) in capital expenditures (CN¥14.73 Million). Check how tangible is Beijing Hotgen Biotech Co Ltd's equity to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Beijing Hotgen Biotech Co Ltd Capital Reinvestment Ratio (2016–2022)
This chart tracks Beijing Hotgen Biotech Co Ltd's Capital Reinvestment Ratio across 7 annual periods. For the full cash flow conversion analysis, see 688068 operating cash flow.
Annual Capital Reinvestment Ratio for Beijing Hotgen Biotech Co Ltd (2016–2022)
Year-by-year Capital Reinvestment Ratio for Beijing Hotgen Biotech Co Ltd from 2016 to 2022. See how much free cash does Beijing Hotgen Biotech Co Ltd generate to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2022 | 0.58x | CN¥978.75 Million | CN¥565.21 Million | ▲ +282.9% |
| 2021 | 0.15x | CN¥2.64 Billion | CN¥398.86 Million | ▼ -85.6% |
| 2020 | 1.05x | CN¥164.62 Million | CN¥172.27 Million | ▼ -77.1% |
| 2019 | 4.57x | CN¥19.37 Million | CN¥88.48 Million | ▲ +498.5% |
| 2018 | 0.76x | CN¥55.04 Million | CN¥42.00 Million | ▼ -74.6% |
| 2017 | 3.01x | CN¥22.95 Million | CN¥69.05 Million | ▲ +546.9% |
| 2016 | 0.47x | CN¥45.54 Million | CN¥21.18 Million | — |